Harshwardhan Singh

931 total citations · 1 hit paper
26 papers, 574 citations indexed

About

Harshwardhan Singh is a scholar working on Organic Chemistry, Molecular Biology and Computational Theory and Mathematics. According to data from OpenAlex, Harshwardhan Singh has authored 26 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Organic Chemistry, 13 papers in Molecular Biology and 9 papers in Computational Theory and Mathematics. Recurrent topics in Harshwardhan Singh's work include Synthesis and biological activity (15 papers), Computational Drug Discovery Methods (9 papers) and Melanoma and MAPK Pathways (6 papers). Harshwardhan Singh is often cited by papers focused on Synthesis and biological activity (15 papers), Computational Drug Discovery Methods (9 papers) and Melanoma and MAPK Pathways (6 papers). Harshwardhan Singh collaborates with scholars based in India, Russia and Saudi Arabia. Harshwardhan Singh's co-authors include Ankit Kumar Singh, Pradeep Kumar, Adarsh Kumar, Amita Verma, Prateek Pathak, Maria Grishina, Mariusz Jaremko, Abdul‐Hamid Emwas, Habibullah Khalilullah and Suresh Thareja and has published in prestigious journals such as Scientific Reports, RSC Advances and Drug Discovery Today.

In The Last Decade

Harshwardhan Singh

24 papers receiving 563 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective

2023 181 citations Adarsh Kumar, Ankit Kumar Singh et al. Pharmaceuticals profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Harshwardhan Singh India	9	341	223	119	67	29	26	574
Mohammad Nadeem Lone India	9	313 0.9×	157 0.7×	103 0.9×	42 0.6×	23 0.8×	13	583
Yunlei Hou China	17	427 1.3×	254 1.1×	129 1.1×	52 0.8×	19 0.7×	64	734
Merve Erkısa Türkiye	16	260 0.8×	254 1.1×	245 2.1×	37 0.6×	39 1.3×	37	687
Anja Harej Croatia	12	355 1.0×	140 0.6×	78 0.7×	36 0.5×	24 0.8×	22	488
Feijie Xu China	14	385 1.1×	213 1.0×	70 0.6×	31 0.5×	14 0.5×	16	622
Zhangxu He China	12	192 0.6×	273 1.2×	112 0.9×	31 0.5×	14 0.5×	28	491
Marwa G. El‐Gazzar Egypt	17	622 1.8×	310 1.4×	99 0.8×	53 0.8×	21 0.7×	42	789
Abhishek Sharma United States	18	686 2.0×	225 1.0×	80 0.7×	40 0.6×	56 1.9×	45	936
Kapil Juvale India	15	260 0.8×	312 1.4×	340 2.9×	70 1.0×	34 1.2×	37	801
Hussien Ahmed Khamees India	12	256 0.8×	147 0.7×	85 0.7×	36 0.5×	36 1.2×	28	513

Countries citing papers authored by Harshwardhan Singh

Since Specialization

Citations

This map shows the geographic impact of Harshwardhan Singh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harshwardhan Singh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harshwardhan Singh more than expected).

Fields of papers citing papers by Harshwardhan Singh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harshwardhan Singh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harshwardhan Singh. The network helps show where Harshwardhan Singh may publish in the future.

Co-authorship network of co-authors of Harshwardhan Singh

This figure shows the co-authorship network connecting the top 25 collaborators of Harshwardhan Singh. A scholar is included among the top collaborators of Harshwardhan Singh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harshwardhan Singh. Harshwardhan Singh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kumar, Adarsh, Ankit Kumar Singh, Harshwardhan Singh, et al.. (2025). Synthesis and anticancer evaluation of novel pyrrole-pyrido[2,3-d] pyrimidine-based compounds as thymidylate synthase inhibitors. Journal of Molecular Structure. 1336. 142053–142053. 2 indexed citations

Prajapati, Vimal H., Ankit Kumar Singh, Adarsh Kumar, et al.. (2025). Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective. RSC Medicinal Chemistry. 16(5). 1923–1940. 2 indexed citations

Singh, Ankit Kumar, Adarsh Kumar, Harshwardhan Singh, et al.. (2025). Targeted design, synthesis, molecular dynamics, ADME and in –vitro anticancer assessment of oxo-tetrahydro-pyrimidin-benzenesulfonamide hybrids as potential BRAFV600E inhibitors. Scientific Reports. 15(1). 35088–35088. 1 indexed citations

Kumar, Adarsh, Ankit Kumar Singh, Harshwardhan Singh, Balasubramanian Narasimhan, & Pradeep Kumar. (2024). Synthesis and Anticancer Evaluation of Benzylated Indole Based Alkyl‐Substituted Pyrido[2,3‐ d ]Pyrimidines Targeting Thymidylate Synthase. ChemistrySelect. 9(15).

Singh, Ankit Kumar, Prateek Pathak, Adarsh Kumar, et al.. (2024). Design, Virtual Screening, Molecular Docking, ADME and Cytotoxicity Studies of 1,3,5-Triazine Containing Heterocyclic Scaffolds as Selective BRAF Monomeric, Homo and Heterodimeric Inhibitors. Combinatorial Chemistry & High Throughput Screening. 28(13). 2351–2368. 1 indexed citations

Singh, Ankit Kumar, Adarsh Kumar, Harshwardhan Singh, et al.. (2024). Semisynthetic phytochemicals in cancer treatment: a medicinal chemistry perspective. RSC Medicinal Chemistry. 15(10). 3345–3370. 2 indexed citations

Agrawal, Shikha, et al.. (2024). A comprehensive review on pharmacognosy, phytochemistry and pharmacological activities of 8 potent species of southeast Asia.. PubMed. 44(3). 620–628. 2 indexed citations

Kumar, Adarsh, et al.. (2023). In Silico Studies of Indole Derivatives as Antibacterial Agents. Journal of pharmacopuncture. 26(2). 147–157. 6 indexed citations

Kumar, Adarsh, Jurica Novak, Ankit Kumar Singh, et al.. (2023). Virtual screening, structure based pharmacophore mapping, and molecular simulation studies of pyrido[2,3-d]pyrimidines as selective thymidylate synthase inhibitors. Journal of Biomolecular Structure and Dynamics. 41(23). 14197–14211. 7 indexed citations

10.

Singh, Ankit Kumar, Adarsh Kumar, Harshwardhan Singh, et al.. (2023). Description and In silico ADME Studies of US-FDA Approved Drugs orDrugs under Clinical Trial which Violate the Lipinski’s Rule of 5. Letters in Drug Design & Discovery. 21(8). 1334–1358. 14 indexed citations

11.

Kumar, Adarsh, Ankit Kumar Singh, Harshwardhan Singh, et al.. (2023). Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective. Pharmaceuticals. 16(2). 299–299. 181 indexed citations breakdown →

12.

Singh, Harshwardhan, et al.. (2023). Medicinal Chemistry Aspects of Isoxazole Analogues as Anti-tubercular Agents. Current Organic Chemistry. 27(15). 1308–1318. 1 indexed citations

13.

Kumar, Adarsh, et al.. (2023). Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer. Drug Discovery Today. 29(1). 103853–103853. 4 indexed citations

14.

Kumar, Adarsh, et al.. (2023). Synthetic Methodologies and SAR of Quinazoline Derivatives as PI3K Inhibitors. Anti-Cancer Agents in Medicinal Chemistry. 23(9). 1013–1047. 1 indexed citations

15.

Kumar, Adarsh, Ankit Kumar Singh, Harshwardhan Singh, et al.. (2023). Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents. RSC Advances. 13(10). 6872–6908. 39 indexed citations

16.

Kumar, Pradeep, et al.. (2023). Molecular Docking and QSAR Studies of Indole Derivatives as AntifungalAgents. 3. 3 indexed citations

17.

Singh, Ankit Kumar, Adarsh Kumar, Harshwardhan Singh, et al.. (2023). Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022. ACS Omega. 8(31). 27819–27844. 24 indexed citations

18.

Singh, Ankit Kumar, Prateek Pathak, Adarsh Kumar, et al.. (2023). Design, one-pot synthesis, computational and biological evaluation of diaryl benzimidazole derivatives as MEK inhibitors. Journal of Biomolecular Structure and Dynamics. 42(21). 11812–11827. 4 indexed citations

19.

Kumar, Adarsh, Ankit Kumar Singh, Harshwardhan Singh, Suresh Thareja, & Pradeep Kumar. (2022). Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer. Medical Oncology. 40(1). 3–3. 36 indexed citations

20.

Singh, Ankit Kumar, Jurica Novak, Adarsh Kumar, et al.. (2022). Gaussian field-based 3D-QSAR and molecular simulation studies to design potent pyrimidine–sulfonamide hybrids as selective BRAF^V600Einhibitors. RSC Advances. 12(46). 30181–30200. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact